Genzyme, Daiichi allow Impax to launch a generic Welchol

06/30/2011 | Reuters

Generic-drug maker Impax Laboratories resolved a patent dispute with Genzyme and Daiichi Sankyo regarding diabetes pill Welchol. The settlement allows Impax to market its version on March 2, 2015, or earlier under certain conditions.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA